Therapeutic effect of Biyuan tongqiao granules combined with mometasone furoate nasal spray on clinical symptoms of children with allergic rhinitis

Objective: To explore the clinical benefits of Biyuan Tongqiao granules (BTG) combined with mometasone furoate nasal spray (MFNS) on the symptoms of children with allergic rhinitis (AR). Methods: Seventy-eight children with AR who visited the Pediatric Department of our hospital from May 2019 to May 2020 were selected and randomly divided into the BTG group (treated with BTG alone), MFNS group (treated with MFNS alone), and combined group (children with the combined use of BTG and MFNS), with 26 cases in each group. The nasal symptoms and oculonasal symptoms were evaluated and observed at baseline and 2 months after treatment. Results: Children in the combination group had significantly lower total nasal symptom score (TNSS), total non-nasal symptom score (TNNSS) scores, and visual analogue scale (VAS) scores than those with BTG alone and MFNS alone (P<0.05). The overall response rate was 69.23% in children with BTG alone, 80.77% in children with MFNS alone, and 92.31% in children with the combined treatment. Conclusion: BTG combined with MFNS can improve the symptoms of sneezing and nasal congestion, which is better than single drug treatment.